Clinical trial NCT02570113: The Peregrine Post-Market Study for the Treatment of Hypertension
Official title: A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: Ablative Solutions, Inc.
Sponsor class: INDUSTRY
First posted: 2015-10-07
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Ablative Solutions, Inc. Peregrine System Infusion Catheter is a catheter-based device which is intended to be used to ablate the afferent and efferent sympathetic nerves serving the kidneys. The catheter is inserted via the femoral artery, steered into the renal artery, and then delivers, by infusion from its distal end, a neurolytic agent. This targets the nerve bundles, which are in the adventitia - a sheath surrounding the artery. The aim is to reduce blood pressure in cases of hypertension, including seriously elevated blood pressure which does not respond to drug treatment. This study will evaluate the safety and performance of the device.

Detailed description: There is strong evidence in the published literature that the renal nerves are important contributors to hypertension, and that their ablation does not have adverse side-effects.

The literature provides technical, clinical and scientific evidence supporting the use of perivascular renal denervation for a carefully defined patient group.

An existing device (the Medtronic Symplicity catheter) was initially shown to be safe and effective for achieving perivascular renal denervation by delivery of radio-frequency energy. The results of early nonrandomized clinical studies (HTN-1, HTN-2) found that perivascular renal denervation by radio-frequency energy delivery was an effective therapy, associated with very low risks. In other contexts, denervation can also be safely and effectively achieved by neurolytic agents.

The ASI Peregrine System™ Infusion Catheter and the denervation procedure in general is similar enough to the Medtronic Symplicity catheter to enable the use of published data to establish the validity of the design concept of the Peregrine System and estimate the likely levels of risk of side effects. It can be concluded from the literature that the ASI Peregrine System™ will achieve percutaneous renal denervation with a low risk of procedural complications (comparable to accepted percutaneous interventional therapies) and without long-term impairment of renal artery or kidney function or other serious adverse events.

Previous premarket clinical trials have provided support for the safe and effective use of the Peregrine Catheter for the treatment of patients with hypertension. The Peregrine System Infusion Catheter is currently CE marked and the indication for use is "The Peregrine System™ Infusion Catheter is intended for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients." Based upon the literature and previous clinical data, chemical denervation is an appropriate treatment for the specified study population of adults who have hypertension despite taking at least 3 anti-hypertensive drugs of different classes including at least one diuretic.

The objectives of this post-market study are to collect additional safety and performance data pertaining to renal denervation by using dehydrated alcohol as a chemical neurolytic agent delivered into the adventitial/peri-adventitial area of the renal arteries for the purpose of renal denervation, using the Peregrine System™ Infusion Catheter, in patients with hypertension.

In order for the study to be valid, only one chemical neurolytic agent can be used. The Coordinating Investigator has chosen to use dehydrated alcohol (not less than 95% by volume) for therapeutic neurolysis, therefore all participating sites will use this agent.

Eligibility criteria: Inclusion Criteria:

1. Adult subject, age 18-80, male or female;
2. Subject has a target treatment vasculature diameter of ≥4 mm and ≤ 7 mm and length of ≥5 mm;
3. Subject has 3 measurements with a mean of office Systolic Blood Pressure of

   ≥150 mmHg AND office Diastolic Blood Pressure of ≥85 mmHg;
4. Subject has a 24-hour mean systolic Ambulatory Blood Pressure Measurement (ABPM) ≥135 mm Hg with ≥70% valid readings (as determined by measurement device);
5. Subject with hypertension is receiving and adhering to a stable medication regimen of at least 3 anti-hypertensive medications of different classes (for at least 4 consecutive weeks), one of which must be a diuretic;
6. Subject agrees to have all study procedures performed, to comply with medication regimen and is able and willing to comply with all study follow-up visits;
7. Subject has provided written informed consent.

Exclusion Criteria:

1. Subject has a contraindication known for conventional percutaneous interventional procedures such as:

   * intolerance for antiplatelet/anticoagulant therapy
   * known allergy to contrast media
   * bleeding disorders (such as bleeding diathesis, thrombocytopenia and severe anemia)
2. Subject has documented severe untreated obstructive sleep apnea (Apnea Hypopnea Index \[AHI\] ≥30 per hour);
3. Subjects with nephrotic syndrome;
4. Subjects on immunosuppressive medications or immunosuppressive doses of steroids;
5. Subject has type 1 diabetes mellitus;
6. Subject is pregnant or nursing or planning to become pregnant;
7. Subject has an eGFR ≤20 mL/min/1.73m2

   , based on the CKD-EPI equation;
8. Subject has imaging-assessed renal artery anatomy abnormalities or variations based on Investigator's evaluation of the screening images \[i.e. MRA/CTA examination and/or renal angiography\]) meeting one of the following criteria:

   * Renal artery stenosis \>60% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment);
   * Any renal artery abnormality or disease that, per the physician assessment, precludes the safe insertion of the guiding catheter (such as but not limited to severe renal artery aneurysm, excessive tortuosity, severe renal artery calcification);
   * Previous renal angioplasty associated with stenting or other implants, that, per the physician's assessment, precludes the safe deployment of the Peregrine catheter components in the target treatment segment of the renal artery;
9. Subject has a history of nephrectomy, a single kidney or kidney tumor, or urinary tract obstruction (with potential for hydronephrosis);
10. Subject is known to have a non-functioning kidney or unequal renal size (\>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function);
11. Subject has a renal transplant;
12. Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within the last six months from planned procedure;
13. Subject has hemodynamically significant valvular heart disease;
14. Subject has heart failure (NYHA III or IV) or has an ejection fraction ≤30%;
15. Subject with chronic atrial fibrillation;
16. Subjects who are allergic or intolerant of the neurolytic agent (such as dehydrated alcohol);
17. Any contraindication to the imaging as required per the protocol;
18. Subject has a life expectancy of \<12 months;
19. Subject is currently enrolled in other potentially confounding research, i.e., another therapeutic or interventional research trial. Subjects enrolled in observational registries may still be eligible.

Primary outcomes:
measure: Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure:
timeFrame: 1-month
measure: Change in 24-hour Mean Ambulatory Systolic Blood Pressure From Baseline to 6 Months
timeFrame: 6 months
Secondary outcomes:
measure: Numbr of Subjects With a Decline in eGFR by >25% From Baseline to 6 Months
timeFrame: 6 months
measure: Change in Serum Creatinine From Baseline to 6 Months
timeFrame: 6 months
measure: Number of Participants With New Renal Arterial Stenosis > 60%
timeFrame: 6 months
measure: Number of Subjects With Stroke or Transient Ischemic Attack (TIA) With 1 Month of the Procedure
timeFrame: 1 month
measure: Number of Subjects With Myocardial Infarction (MI) Within 1 Month of the Procedure
timeFrame: 1 month
measure: Number of Participants With Major Adverse Events (MAE) Through 6 Months Post-Procedure
timeFrame: 6 months
measure: Changes in Antihypertensive Medications at 7 Days, and 1, 3, 6 and 12 Months Post-Procedure
timeFrame: 7-day, 1, 3, 6 and 12 months
measure: Changes in Systolic and Diastolic Clinic/Office Blood Pressure
timeFrame: 7-day, 1, 3, 6 and 12 months
measure: Changes in Systolic and Diastolic 24-hour Mean Daytime and Nighttime Ambulatory Blood Pressure
timeFrame: 1, 3, 6 and 12-months
measure: Changes in Diastolic 24-hour Mean Ambulatory Blood Pressure
timeFrame: 1, 3, 6 and 12-months
measure: Changes in Systolic 24-hour Mean Ambulatory Blood Pressure
timeFrame: 1, 3 and 12 months
measure: Change in eGFR
timeFrame: 1, 3, 6 and 12 months
measure: The Progression of Kidney Disease
timeFrame: 1, 3, 6, and 12 months
measure: Change in Albuminuria
timeFrame: 3, 6, and 12 months
measure: Change in Albuminuria Categorization
timeFrame: 3, 6, and 12 months
measure: Change in Serum Creatinine and Cystatin-C
timeFrame: 3, 6, and 12 months
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Prague
country: Czechia
facility: Na Homolce Hospital
city: Berlin
country: Germany
facility: Charite-Universitaetsmedizin Berlin
city: Erlangen
country: Germany
facility: Universitätsklinik Erlangen Klinik für Nephrologie/Hypertensiologie
city: Essen
country: Germany
facility: Elisabeth-Krankenhause
city: Frankfurt
country: Germany
facility: CardioVasculares Centrum (CVC) Frankfurt
city: Freiburg
country: Germany
facility: Universitats-Herzzentrum/University Heart Center Klinik fur Kardiologie und Angiologie
city: Homburg
country: Germany
facility: Klinik fur Innere Medizin III
city: Tychy
country: Poland
facility: Oddzial Kardiologii Inwazyjnej
city: Ustron
country: Poland
facility: Oddizal Kardiologiczno-Angiologiczny PAKS
Study officials:
affiliation: CardioVasculares Centrum (CVC) Frankfurt
name: Horst Sievert, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mahfoud F, Sievert H, Bertog S, Lauder L, Ewen S, Lengele JP, Wojakowski W, Schmieder R, van der Giet M, Weber MA, Kandzari DE, Parise H, Fischell TA, Pathak A, Persu A. Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circ Cardiovasc Interv. 2021 Sep;14(9):e010075. doi: 10.1161/CIRCINTERVENTIONS.120.010075. Epub 2021 Sep 2.